AURELIA ONLINEHow Long Can You Use Mounjaro 12.5 mg or 15 mg? Long-Term Use, Maintenance Dosing and Dose Reduction
This English page provides medical information and booking guidance. Consultation may be conducted in Japanese or English. Tell the doctor the country where you are physically located. Medication supplied through this service is received in Japan by the patient; proxy pickup and direct overseas delivery are not supported.
There is no simple rule that Mounjaro 12.5 mg or 15 mg can only be used for a fixed number of months. Long-term use is guided by ongoing benefit, safety, glucose control, weight trajectory, nutrition and whether the current high dose is still necessary.
- The Japanese Mounjaro label does not state a universal “15 mg for only X months” limit.
- 15 mg is the maximum dose, but it does not have to remain the lifelong maintenance dose.
- Long-term tirzepatide trial data extend to 176 weeks.
- In 2026 SURMOUNT-MAINTAIN, reducing from maximum tolerated 10/15 mg to 5 mg still preserved meaningful average weight loss, although less than staying on the maximum tolerated dose.
- Stopping completely led to more regain than continuing treatment in withdrawal trials.
What does the Japanese label say about duration?
The label focuses on response and safety rather than a fixed maximum treatment duration. It permits dose reduction according to the patient’s condition, recommends considering dose reduction or delayed escalation when GI tolerability is poor, and warns clinicians to monitor excessive weight loss.
What do 3-year data show?
In the 176-week SURMOUNT-1 extension among participants with obesity and prediabetes, mean weight change at week 176 was −12.3% with 5 mg, −18.7% with 10 mg and −19.7% with 15 mg, compared with −1.3% with placebo. The main adverse events remained gastrointestinal and no new safety signal was reported during the study period.
Can a lower maintenance dose work after high-dose weight loss?
SURMOUNT-MAINTAIN directly tested maintenance strategies after 60 weeks at maximum tolerated 10 mg or 15 mg. Participants then continued the maximum tolerated dose, reduced to 5 mg, or switched to placebo.
| Strategy | Mean weight change from original baseline at week 112 |
|---|---|
| Continue maximum tolerated dose | −21.9% |
| Reduce to 5 mg | −16.6% |
| Switch to placebo | −9.9% |
This shows that a lower maintenance dose can preserve substantial average weight loss for some people, while also showing that remaining on the higher dose preserved more loss on average.
Does this tell us exactly what happens with 15 mg → 12.5 mg?
No. SURMOUNT-MAINTAIN compared a 5 mg maintenance arm, not a dedicated 12.5 mg maintenance arm. Do not estimate a 12.5 mg maintenance percentage by averaging trial numbers.
What happens if tirzepatide is stopped?
In SURMOUNT-4, after substantial initial weight loss, those who continued tirzepatide lost another 5.5% on average from week 36 to 88, while the placebo-switch group regained 14.0% on average. Stopping after reaching a goal therefore needs a maintenance plan rather than assuming weight will remain unchanged.
When might a high dose be reduced?
- Target weight has been reached and the goal has shifted to maintenance.
- Nausea, constipation or other GI symptoms remain burdensome.
- Food intake is too low or nutrition is becoming difficult.
- Weight is falling excessively or strength is declining.
- A lower dose may be enough to maintain glucose/weight goals.
When might continuing 12.5 mg or 15 mg make sense?
Continuation may be reasonable when the current dose clearly maintains glucose/weight benefit, side effects are mild, nutrition and hydration are adequate, and previous attempts at lower doses led to clinically important deterioration.
Maintenance dosing is not a contest to reach the smallest dose
The goal is the lowest burden that reliably maintains the necessary clinical benefit—not simply the lowest possible number on the pen. Some patients may maintain on 5 mg or 10 mg; others may require 12.5 mg or 15 mg.
Long-term monitoring
| Monitor | Why |
|---|---|
| Weight/waist | Excess loss or regain |
| HbA1c/glucose | Type 2 diabetes control |
| Food/fluid intake | Nutrition and dehydration |
| GI symptoms/bowel function | Tolerability and ileus warning signs |
| Strength/activity | Functional and lean-mass concerns |
Long-term treatment is chronic-disease management, not “dependence”
Weight regain after withdrawal is not evidence of addiction. Obesity and type 2 diabetes are chronic conditions with biological drivers. Some patients require ongoing pharmacologic treatment, while others may be able to reduce the maintenance dose with monitoring.
Frequently asked questions
How many months can I stay on Mounjaro 15 mg?
The Japanese label does not set a universal maximum number of months. Ongoing use depends on benefit, safety and the treatment goal.
Do I have to stay on 15 mg forever once I reach it?
No. A lower maintenance dose may be considered when clinically appropriate.
Can 5 mg maintain weight after 10/15 mg?
SURMOUNT-MAINTAIN showed meaningful average maintenance after reduction to 5 mg, but maximum-tolerated-dose continuation preserved more loss on average.
Will stopping Mounjaro cause regain?
Not everyone responds identically, but randomized withdrawal trials showed substantial average regain after tirzepatide was stopped.
References
- PMDA. Mounjaro Japanese package insert, revision September 2026.
- Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025.
- Horn DB, et al. SURMOUNT-MAINTAIN. Lancet. 2026.
- Aronne LJ, et al. SURMOUNT-4. JAMA. 2024.
In Japan, Mounjaro is approved for type 2 diabetes. Use of Mounjaro for weight management is off-label. Obesity-trial data are cited as medical evidence about tirzepatide, not as a statement that Mounjaro is approved for obesity in Japan.